More than 200 chief executives from the world of British biotechnology have united in a passionate appeal to the Chancellor, warning that proposed increases in taxes or business rates for
Biotech
22Articles
An unexpected breakthrough by three British biologists could revolutionise the way breast milk is stored, presenting both health and commercial prospects for families and investors alike. BoobyBiome, a biotechnology start-up
World leaders gathered in Beijing were momentarily caught off guard when Xi Jinping, Vladimir Putin and Kim Jongun were overheard discussing the future of human longevity and the potential for
A leading biopharmaceutical business saw its shares tumble by almost 40 per cent after results from a trial of its much-anticipated weight loss pill failed to meet market expectations. Viking
Shares in Oxford Nanopore surged as the FTSE 250 gene-sequencing specialist reported stronger than expected sales for the first half of 2025. The company expects to post revenues of around
In a landmark transaction, US pharmaceutical behemoth Merck has secured the acquisition of London-based Verona Pharma for approximately $10 billion, marking a significant milestone in the biotech sector. The deal
In a significant shift for the UK’s life sciences sector, Syncona, the Wellcome Trust-backed FTSE 250 investment company, has revealed plans to implement an orderly wind-down of its portfolio assets.
Australian biotechnology company BPH Global has unveiled groundbreaking research revealing significant concentrations of gold and copper in seaweed, opening new possibilities for sustainable metal extraction from seawater. Recent assays conducted
Synairgen, the respiratory-focused biotechnology company born out of the University of Southampton, is set to delist from the Alternative Investment Market (AIM) following a turbulent period of funding challenges. Shareholders
British pharmaceutical giant GSK has struck a significant deal worth up to $1.15 billion to acquire IDRx, a Massachusetts-based biopharmaceutical company, strengthening its position in the oncology sector. The FTSE
Shares in Oxford Nanopore Technologies jumped 8.9 per cent today after the British gene sequencing innovator reported robust revenue growth and reaffirmed its path to profitability. The FTSE 250 company
In a significant move that marks the largest biotech acquisition since 2023, Johnson & Johnson has announced its agreement to purchase neuroscience drugmaker Intra-Cellular Therapies for £14.6 billion. The New
In a devastating blow to investor confidence, Moderna’s shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant.
Liverpool’s burgeoning life sciences sector is positioning itself as one of Europe’s premier biotech clusters, with projections indicating up to £800 million in investment over the next decade. The region’s
A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as
British pharmaceutical giant GSK is in advanced negotiations to acquire IDRx, a Massachusetts-based biotechnology company, in a deal valued at approximately $1 billion. The announcement is expected to coincide with
- 1
- 2
